SCHEMBL30008969

SCHEMBL30008969

CCNC(=S)Nc1ccc(-c2ncnc3[nH]ccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 4/20 0.58
CIT O14578 1/20 0.56
JAK2 O60674 2/20 0.51
IKBKB O14920 1/20 0.48
CHUK O15111 1/20 0.48
ROCK2 O75116 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP3A5 P20815 1/20 0.48
LIMK1 P53667 1/20 0.48
BTK Q06187 4/20 0.47
JAK3 P52333 4/20 0.47
MELK Q14680 1/20 0.47
FLT3 P36888 2/20 0.47
PDGFRB P09619 1/20 0.47
KIT P10721 1/20 0.47
MAP3K19 Q56UN5 1/20 0.47
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009899 0.91 JAK1 (0.59) JAK1CITJAK2IKBKBCHUK
SCHEMBL30009446 0.89 JAK1 (0.61) JAK1CITJAK2IKBKBCHUK
SCHEMBL30009442 0.85 CIT (0.62) JAK1CITJAK2IKBKBCHUK
SCHEMBL30009331 0.81 CIT (0.58) JAK1CITJAK2IKBKBCHUK
SCHEMBL30009617 0.77 JAK1 (0.63) JAK1CITJAK2IKBKBCHUK
SCHEMBL30009593 0.77 RAB9A (0.51) CITJAK2ROCK2CYP3A4CYP3A5
SCHEMBL28871098 0.77 CIT (0.63) JAK1CITJAK2IKBKBCHUK
SCHEMBL20930342 0.74 JAK1 (1.00) JAK1
SCHEMBL30009248 0.73 IKBKB (0.61) JAK1CITJAK2IKBKBCHUK
SCHEMBL28345572 0.72 JAK3 (0.74) JAK1CITJAK2IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 JAK1 83/4885CIT 417/4885JAK2 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.